| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
78 |
| Employees |
190 |
| Revenues (TTM) (Millions $) |
193 |
| Net Income (TTM) (Millions $) |
-124 |
| Cash Flow (TTM) (Millions $) |
-39 |
| Capital Exp. (TTM) (Millions $) |
12 |
Business Description
Dicerna Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi) therapeutics for the treatment of various diseases. The company is based in Lexington, Massachusetts and was founded in 2007, by a team of RNAi experts including Dr. James E. J. Bedard, Dr. Douglas M. Fambrough, and Dr. Dale L. Ludwig.
RNA interference is a natural process that cells use to silence or turn off the expression of a specific gene. Dicerna Pharmaceuticals is focused on using this process to target and treat a range of genetic diseases including cancer, liver diseases, viral infections, and rare genetic disorders.
The company has developed a proprietary platform called the Dicer substrate technology (DST) which enables the design and delivery of highly specific RNAi therapies. The DST platform focuses on enhancing the stability and specificity of RNAi molecules, which facilitates the development of RNAi therapies with improved therapeutic potential.
Dicerna Pharmaceuticals is currently in the process of developing multiple RNAi therapeutics, including its lead product candidate, DCR-PHXC, a treatment for primary hyperoxaluria (PH). PH is a rare, inherited metabolic disease that causes the buildup of oxalate in the kidneys, leading to kidney damage and failure. Dicerna Pharmaceuticals is also developing RNAi therapeutics for the treatment of other liver diseases, including hepatitis B and nonalcoholic steatohepatitis (NASH).
The company has a strategic partnership with Roche to develop RNAi therapeutics for the treatment of hepatitis B, and with Eli Lilly to develop RNAi therapeutics for the treatment of cardiovascular disease.
Dicerna Pharmaceuticals has also been recognized for its work in the RNAi field, receiving grants from organizations such as the National Institutes of Health (NIH), the Massachusetts Life Sciences Center (MLSC), and the Bill & Melinda Gates Foundation.
In summary, Dicerna Pharmaceuticals Inc is a clinical-stage company focused on using RNAi therapeutics to treat a range of genetic diseases. Its proprietary DST platform enables the design and delivery of highly specific RNAi therapies, and the company is currently developing multiple RNAi therapeutics for the treatment of various liver diseases and rare genetic disorders.
Company Address: 75 Hayden Avenue Lexington 2421 MA
Company Phone Number: 621-8097 Stock Exchange / Ticker: NASDAQ DRNA
|
%
1.68% 